Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies
Crossref DOI link: https://doi.org/10.1007/s40262-016-0446-8
Published Online: 2016-09-15
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lott, Dominik
Lehr, Thorsten
Dingemanse, Jasper
Krause, Andreas
Funding for this research was provided by:
Actelion Pharmaceuticals
License valid from 2016-09-15